Combination therapies for various cancers have been shown to increase efficacy, lower toxicity, 19 and circumvent resistance. However, despite the promise of combinatorial therapies, the 20 biological mechanisms behind drug synergy have not been fully characterized, and the 21 systematic testing of all possible synergistic therapies is experimentally infeasible due to the 22 47
sheer volume of potential combinations. Here we apply a novel big data approach in the 23 evaluation and prediction of drug synergy by using the recently released NCI-ALMANAC. We 24 found that each traditional drug synergy metric (Bliss, Loewe, ZIP, HSA, ALMANAC Score) 25 identified unique synergistic drug pairs with distinct underlying joint mechanisms of action. 26 Leveraging these findings, we developed a suite of context specific drug synergy predictive 27 models for each distinct synergy type and achieved significant predictive performance (AUC = 28 0.89-0.953). Furthermore, our models accurately identified clinically tested drug pairs and 29 characterized the clinical relevance of each drug synergy metric, with Bliss Independence 30 capturing clinically tested combinations best. Our findings demonstrate that drug synergy can be 31 obtained from numerous unique joint mechanisms of action, captured by different synergy 32 metrics. Additionally, we show that drug synergy, of all kinds, can be predicted with high 33 degrees of accuracy with significant clinical potential. This breakthrough understanding of joint 34 mechanisms of action will allow for the design of rational combinatorial therapeutics on a large Drug combination efficacy metrics have been crucial in the development of synergistic drug 101 treatments, however there has yet to be an in-depth evaluation of these metrics across diverse 102 drug and cancer types. The diversity of the publically available data set, NCI-ALMANAC, 103
provided the opportunity for us to test the different combination efficacy measures across various 104 cancer types and drug classes. We first interrogated the diversity of the NCI-ALMANAC dataset 105 and found that they tested over 100 drugs, which represented 12 distinct drug classes ( Figure  106 1A), in pairwise drug efficacy screenings on 60 cell lines. The 60 cancer cell lines tested cover 9 107 diverse cancer types ( Figure 1B) . In addition to the experimental data, the NCI-ALMANAC 108 formulated their own drug synergy score (we will refer to this metric as the ALMANAC score) 109 and have released this score for each pairwise combination 17 . 110 111
The disparity and diversity among combination efficacy metrics has long been remarked on 12 112
and we verified this quantitatively by looking at the correlation between each synergy metric on 113 the NCI-ALMANAC drug pairs for each cell line (Figure 1C, Supp Fig 1) . We found the 114 correlation between synergy measures using both Pearson and Spearmen, with the coefficients 115 ranging from 0.21-0.66 (p < 0.001) and 0.18-0.84 (p <0.001), respectively. Only HSA and 116
Loewe had a Pearson and Spearman correlation above 0.5 (Methods). Importantly, we also 117 found that the majority of both the synergistic and antagonistic qualifications assigned to drug 118 pairs were unique to efficacy metrics ( Figure 1D) , even in the case of measures that were highly 119 correlated (proportion overlap 0.40 and 0.35 for HSA and Loewe, HSA and ZIP, respectively). 120
These results illustrate the distinctness between combination efficacy metrics across many drug 121 and cancer types. 122 123
Synergistic Drug Pairs Share Distinct Attributes 124 125
Drug synergy can arise due to a variety of diverse mechanisms which may present as distinct 126 patterns in in vitro assays 18, 19 . Due to the large discrepancy between combination efficacy 127 metrics we reasoned that each metric may be identifying different types of synergistic 128
combinations. Therefore, we looked to quantify which drug attributes were shared among all 129 synergistic drug pairs and which were metric specific. Since we have previously found drug 130 structure to effect pharmacological attributes such as toxicity and molecular targets 20-22 , we 131 investigated if structure based similarity between drug pairs was indicative of a pair being 132 synergistic. Using chemical fingerprint similarity, we found that synergistic pairs were more 133 similar to each other than antagonistic and other non-synergistic drugs, across all metrics (KS 134 test, D-stat 0.23-0.307, p-value < 0.001, Figure 2A ). Antagonistic and uncategorized, drug pairs 135
were associated with undistinguishable levels of structure similarity (KS Test, p-value > 0.05). 136
When we evaluated additional structure comparison measures, such as the similarity of hydrogen 137 atoms and bonds our findings remained consistent (Supp Fig 2) , we found that regardless of 138 combination efficacy metric, drug synergy scores increased directly with drug structure 139 similarity. These results run counter to expectations that synergistic drugs target distinct 140 pathways. 141 142
We further investigated drug attributes that could characterize synergistic drug pairs and focused 143 on molecular targets of these drugs, which has also been shown to effect numerous other 144 pharmacological attributes in past research 20, 22 . We found that drug pairs sharing a higher 145 number of the same targets were not more synergistic or antagonistic than expected by chance 146
(KS test, D-stat < 0.1, p-value >0.05), for any metric (Supp Fig 3A) . However, we found that 147 synergistic drugs tended to be found in the same pathway more than antagonistic drugs, as per 148 KEGG pathways, Reactome pathways or molecular function gene ontology (Figure 2B , Supp 149 Fig 3B) . However, since each drug synergy metric is based on different underlying principles, 150
we hypothesized that there would be a large variation in how strongly drug synergy scores are 151 influenced by pathway similarity. We found that the Bliss model (which assumes independence 152 between drugs) tended to induce the lowest pathway similarity difference between synergistic 153
(strong pathway similarity) and antagonistic (low pathway similarity) drug pairs (KS test, D = 154 0.171, p <0.001, Supp Fig 3B) . However, in a model that assumes a more additive effect, such 155 as Loewe, the separation greatly increases (KS test, D = 0.307, p <0.001, Supp Fig 3B) . 156 Therefore, drug synergy metrics which incorporate drug pair interactions may be more strongly 157
affected when drugs target similar pathways. 158 159
Synergy Metrics Identify Unique Synergistic Pathway Combinations 160 161
Drug combination efficacy metrics principally vary in their intrinsic assumptions about drug 162 synergy. Previous work in cancer drug combinations has demonstrated that drug synergy can be 163 achieved through a variety of pathway mechanisms 10 ; therefore each metric is most likely 164 identifying distinct pathway combinations. Using the KEGG database to identify pathways based 165 on the molecular targets of each drug, we evaluated whether the combination of targeting two 166 specific pathways was consistently synergistic or antagonistic for each metric. We specifically 167 evaluated the pathway combinations which were most variable among metrics (ie were 168 significantly enriched for synergy using some metrics and a loss of significance in other metrics) 169
( Figure 2C, Methods) . With the identification of these top differential pathway combinations 170
we investigated the potential causes for the variability between metrics. Pathway combinations 171 such as 'Notch Signaling' with 'One Carbon Pool by Folate' (OR = 2.29, p <0.001) or 'Steroid 172
Hormone Biosynthesis' (Fisher's Exact OR = 2.63, p < 0.001) were significantly more likely to 173 be given high Bliss or ALMANAC scores. These pathways are distantly related, as in having no 174 proteins/compounds in common. Both Bliss Independence and the ALMANAC Score assume 175 little-to no interaction between drugs, therefore it would follow that these metrics are more likely 176
to capture drug combinations targeting distant pathways (Supp Fig 4) To further characterize the mechanistic types of drug synergy each metric identifies we 190
categorized three types of pathway mechanisms at the network level based on Menden et al 10 191
(Methods): same target, same pathway, and parallel pathway. We defined combinations with a 192 "same pathway" mechanism as those whose targets are up/downstream of each other and 193 "parallel pathway" mechanism combinations occurred when the drug targets were upregulated 194 or downregulated by the same gene. We found that the synergy score for all metrics increased 195 significantly for drug pairs that interacted in any of these pathway mechanisms by any 196 mechanism of action, compared to drug pairs that did not (Wilcox p-value <0.05, Figure 2D ). 197
The greatest increase was seen in drug combinations with the same target, specifically when 198 using the ALMANAC score to measure synergy (Wilcox location shift = 5.27, p-value < 0.001, 199 Figure 2D ). These results highlight the importance of having any type of interaction, supported 200 by our finding that synergistic drug combinations for all metrics had lower distance between 201 drug targets in a gene network when compared to antagonistic drug pairs (Supp Fig 3C) , most 202 significantly HSA (D = 0.203, p < 0.001). 203 204
To better understand the pathway mechanisms of drug synergy, we assessed if both drugs were 205
inhibiting, activating or a mix of both (one inhibiting and one activating), using mechanism of 206 action data available for each drug on DrugBank 24 . Using our previously defined mechanisms 207
(same target, same pathway, parallel pathway), we first evaluated the 'same target' mechanism 208
and only looked at drug combinations that had at least one drug target in common. When at least 209 one of the drugs was activating its gene target, the ALMANAC Score was significantly higher 210 (Both drugs activate: Wilcox location shift = 5.27, p-value < 0.001; One drug activates: Wilcox 211 location shift = 4.32, p-value < 0.001, Figure 2D, Supp Fig 5) . However, there was no 212 significant shift in synergy score if both drugs were inhibiting the same gene (Wilcox location 213 shift = 0.388, p-value =0.519). Therefore, the ALMANAC score shows no enrichment in finding 214 combinations of dual inhibitors. All other combination efficacy metrics retained a statistical 215 significant increase in synergy scores when both drugs inhibited the same target. Dual inhibitors 216
have been shown to be successful combination treatments within clinical trials 25, 26 , which might 217 be missed if only using the ALMANAC scoring metric. 218 219
Besides targeting the same gene target, synergistic drug pairs will often target the same or 220 parallel pathways, therefore we wanted to quantify the effect on these pathway mechanisms as 221
well. Again when evaluating the ALMANAC score, synergy scores were significantly increased 222 when drug pairs were interacting in these pathway mechanisms, specifically when at least one 223 drug was an inhibitor and both drugs were targeting the same pathway (Both drugs inhibiting: 224
Wilcox location shift = 5.79 , p-value <0.001, One drug inhibiting: Wilcox location shift = 4.47, 225 p-value <0.001, Supp Fig 6,7) and parallel pathways (Wilcox location shift = 1.72, p-value = 226 0.002, One drug inhibiting: Wilcox location shift = 1.92, p-value <0.001, Supp Fig 6,7) . 227
However, when both drugs activate the same/parallel pathway ALMANAC scores were 228 significantly lower than drug pairs not interacting in that manner (Same Pathway: Wilcox 229 location shift= -0.971, p-value = 0.00907, Parallel Pathway: Wilcox location shift = -2.61, p-230 value < 0.001, Supp Fig 6,7) . We found that synergistic scores were significantly higher for 231 drugs pairs that activated the same or parallel pathways in only two metrics, Loewe Since the synergistic drug combinations showed distinct characteristics when compared to 244 antagonistic or other drug pairs, we reasoned that using a computational approach we could build 245 a classification model to predict drug synergy or antagonism based on the similarity of various 246 pharmacological and genomic attributes. Due to the diverse nature of each combination efficacy 247 metric we chose to build a set of classification models, each fit with the synergistic/antagonism 248 labels found using a specific metric, to create a model toolbox. Additionally, to account for the 249 cell line specificity of drug synergy noted in past research 17 and found within our own data 250 (Figure 1B) , we used a multi-task learning approach, which utilizes the strength of transfer 251 learning 27 while accounting for differences in synergy mechanisms between cell lines/cancer 252 types. 253 254
Our approach, a multi-task learning extreme randomized tree algorithm 28 , was tested with 10 255 fold cross validation using the NCI-ALMANAC data and collected drug similarity features 256 (Methods). Each model, specific to one metric, had significant predictive power, with the area-257
under-the -receiver-operator curve (AUROC) ranging from 0.89-0.95 ( Figure 3A ) and the area-258
under-the-precision-recall curve (AUPRC) ranging from 0.51-0.71 ( Figure 3B) . These strong 259
AUPRCs demonstrate a fair trade-off between false positives and false negatives within our data 260 (Supp Fig 8) . This is one of the highest reported accuracy measures for drug synergy prediction 261 models based on any of these combination efficacy metrics 10, 29 . 262 263
To ensure our results were transferable to external data sets we investigated the AstraZeneca -264 DREAM Challenge drug synergy publically available dataset 10, 11 , which also contained a variety 265 of cancer and drug types. Fig 9) and therefore we used the HSA metric to compare the predicted 271 results. We predicted the drug synergy for all DREAM challenge drug pairs using each model. 272 We found that the predictions were significantly correlated to the calculated AZ-DREAM score 273
(Pearson's Coefficient 0.313, p-value = 0.0493) used in the original research and the calculated 274 HSA (Pearson's Coefficient 0.363, p-value = 0.0213; Figure 3C ). Although the other metrics do 275 not show a statistical significance between calculated and predicted score, this was expected. 276
This experiment was designed with the specific combination AZ-DREAM metric in mind and 277 therefore this was the cleanest data available and most accurate out-of-sample test set. This 278 external independent test set validates the use of our models on different drugs pairs in 279 independent experimental settings. 280 281
Clinical Significance Differs based on Combination Efficacy Metric 282 283
We further assessed our models by applying them to clinically tested pairwise drug combinations 284 found using the Drug Combination Data Base 30 . This database contains drug combinations for a 285 multitude of diseases at different points in the drug development phase, ranging from preclinical 286 to approved. We have limited our scope to drugs that have entered clinical trials for cancer. This 287 subset ensured a fair tradeoff between translatable relevancy and a large enough sample size. 288
Across all combination efficacy metrics our model assigned a significantly higher synergy score 289
to clinically tested drug pairs than randomly selected combinations (D = 0.242-0.297, p < 0.001) 290
( Figure 4A) . While all metrics showed statistical significance, the ALMANAC Score and Bliss 291 metric demonstrated the best ability to distinguish clinically tested and randomly selected drug 292
pairs. This may be due to the popularity of Bliss scores in research, leading to more Bliss 293 synergistic pairs making their way to clinical trials. However, this could be due to the pathway 294 mechanisms enriched within Bliss/ALMANAC score synergistic pairs are more clinically 295
impactful. For example, the targeting of distinct pathways, which the Bliss metric favors, may 296 lead to lower toxicity, which can make those synergistic combinations a clinically viable 297 option 31 . 298 299
In addition to accurately predicting synergistic combinations, we wanted to test if our models, 300 which predict cell-line specific drug synergy, are capable of properly distinguishing which 301 cancer type a combination will be clinically effective within. Across all metrics, predicted 302 synergy scores for clinically tested drug combinations were significantly higher in the cancer cell 303
lines matched with the clinically tested cancer type when compared to randomly selected cell 304 lines (p-value < 0.05, Figure 4b) . The cancer type specificity was comparable for all metric 305 types, demonstrating the robustness of our models and their potential clinical impact. 306 307 DISCUSSION 308
Identifying rational, synergistic drug combinations has great potential to increase efficacy of 309 cancer treatments as well as combat therapeutic resistance, however experimental approaches to 310 pairwise test drug combinations are costly in both time and money. Additionally, there lacks a 311 true gold standard to measure drug synergy, due to the numerous different ways synergistic 312 action can be achieved between two drugs. We have proposed a suite of models to predict drug 313 synergy using the top drug combination efficacy metrics currently available, in addition to 314 identifying the specific types of synergy each metric is tuned to identify. When trained on NCI-315 ALMANAC experimental combination data we achieved significant predictive power across all 316 metrics and showed the ability for these models to be applied to drug combination screenings 317 performed under different conditions, using different drugs and cancer cell lines. Additionally, 318
we have applied these models to drugs in the clinic and accurately distinguished between 319 clinically tested drug combinations and random pairs. Our metric specific suite of models also 320 enables us to identify which efficacy metrics have been most clinical successful and can inform 321 future experimental approaches. 322
323
Drug combinations have long been thought to be the answer to patient resistance and increasing 324 drug efficacy, with notable cases of success 6 . Researchers have realized the impossibility of 325 experimentally testing every pairwise drug combinations and therefore many computational 326 models have been created to answer this very issue 10, 11 . However, many current models were 327 created for either specific drug types or cancer types 8 , which inherently limits the applicability of 328 these models. Recently there was a DREAM Challenge, partnered with AstraZeneca, to predict 329 drug synergy based on diverse drugs and cancer types 10, 11 , however this challenge focused on 330 predicting drug synergy, calculated by only one metric. The metrics used to calculate drug 331 synergy have been shown to be discordant 12 and vary in many of the publically available dataset 332 and the work flows of pharmacological labs or companies. We focused our attention on 333 predicting a bevy of drug synergy types and furthering the understanding of the nuances between 334 drug synergy types. 335 336
While current large-scale experimental approaches have focused on pairwise drug combinations, 337 many drug cocktails (> two drugs) have shown to be promising as therapeutics 32, 33 . Many of the 338 metrics we have discussed can be applied to and measure the drug synergy of these drug 339 cocktails 14, 34 . Since our predictive models are based on drug similarity, this can be easily 340 extended to include more than only two drugs. As experimental methods become more 341 streamlined and less costly, we believe we could extend these models to the prediction of drug 342 synergy for drug cocktails. 343 344
However, drug combination efficacy among cell lines is only one piece of the necessary puzzle 345
to developing synergistic drug combinations. We have not addressed the ongoing issue of 346 toxicity as it pertains to drug combinations, which has led to promising candidates failing in 347 clinical settings 35 . Additionally, our model is not dose specific and therefore cannot be used to 348 identify optimal ratios or doses of drugs for treatments. 349 350
Overall, our suite of models has the potential to quickly predict synergist drug combinations to 351 rapidly speed up the preclinical pipeline for drug combination treatments. Additional, we have 352 outlined the differences between drug synergy metrics in terms of the type of synergistic action 353 they identify and their clinical significance. For the 3,647 drug pairs, multiple compound similarity features were collected. Additionally, using 378 their known drug targets as listed in DrugBank 24 , we collected drug target similarity features as 379
well. The feature, source and metric used to measure similarity is listed in Supplementary Table  380 1. The measures of similarity included but were not limited to Pearson Correlation, Jaccard Index 381
and Dice Similarity. In cases where there was insufficient or missing information, features were 382 imputed by using the median value for that feature in drug pairs with complete information. 383 384
Network Features 385
We curated a biological network that contains 22,399 protein-coding genes, 6,679 drugs, and 170 386
TFs. The protein-protein interactions represent established interaction 38-40 , which include both 387 physical (protein-protein) and non-physical (phosphorylation, metabolic, signaling, and 388 regulatory) interactions. The drug-protein interactions were curated from several drug target 389 databases 40 . 390 391
Predictive Model Suite 392
Our predictive models were trained as binary classifiers using the features described above on the 393 NCI ALMANAC data, with synergistic and antagonistic drug pairs being our respective classes. 394
Every model included the same features, however the classes were determined by one of the five 395 drug synergy measures (HSA, Bliss, Loewe, ZIP, ALMANAC Score). Mulit-task extremely 396 randomized tree models, a decision tree model, was used after model selection and implemented 397 using the R statistical software with the extraTrees package 28 , the cancer cell line was used as each 398 task. To evaluate predictive power 10-fold cross validation was used for each model. Down 399 sampling was the chosen sub-sampling approach applied to each fold to account for the class 400 imbalance between synergistic and antagonistic drug pairs. 401 402
Classification Evaluation 403
For evaluating all the binary synergy classifications, receiver operating characteristic (ROC) and 404 precision-recall curve (PRC) curves were created in R using the pROC 41 and precrec 42 packages 405 respectively. Area-under-the-ROC curve (AUC) and area-under-the-PRC (AUPRC) scores were 406 used to evaluate model performance. 407 408
DREAM Challenge Validation Data 409
Raw dose-response data from the DREAM-AZ Combination Prediction Challenge 10 was used as 410
an external dataset to test our models. We found 19 drug pairs, unseen by the models, available in 411
the Challenge 1 data set tested within cell lines our models were trained on. For these 19 pairs 412
features were collected in the same manner as described above and drug synergy scores for all 413 metrics, besides the ALAMANAC score, were calculated as well. The correlation between all 414 synergy scores were found using Pearson correlations. The synergy scores were predicted using 415 each model and then a Pearson correlation to the calculated scores were measured. Since the 416 calculated HSA score was most significantly correlated with the given DREAM challenge score, 417 the predicted HSA scores were used in the comparison to the DREAM challenge scores. 418 419
Clinical Trial Evaluation 420
Current combinatorial therapeutics in clinical trials were found using the Drug Combination Data 421
Base 30 . Combination therapies were narrowed down to only pairwise combinations of drugs with 422 sufficient information to run the model and combinations being tested to treat cancer, which 423 resulted in 300 unique drug combinations within clinical trials. We created a set of ~250,000 424 random combinations by shuffling the drugs and removing any pairs that were in clinical trials. 425 We then collected all drug compound features as described above and ran them through our 426 model with all cancer cell lines our models have been trained on. Once predictive synergy scores 427
for every metric in all cell lines were obtained we used the mean of scores for each cancer type 428 (based on primary site) to determine the final score of clinically tested combinations. First we 429
tested the difference between clinically tested drug pairs and random drug pairs using 430
Kolmogorov-Smirnov tests. We used a bootstrapping approach to sample the non-clinically 431 tested drug pairs to get a confidence interval of the true model score distribution. Additionally, 432
we used a Kolmogorov-Smirnov test to determine the statistical significance between the scores 433 of our clinically tested drug pairs within the cancer type that is being tested and the drug pairs 434 synergy scores within cancer types that have not been clinically tested. 435 436
Code Availability 437
Our suite of combination models will be available for download upon request to help facilitate 438 immediate impact within the research community. Boxplots of the distribution of synergy scores, predicted by the suite of models, for drug pairs 588 that have been clinically tested and those that have not. The red bars show the confidence 589 interval for the median score of non-clinically tested pairs. B) Violin plots of the distribution of 590
predicted synergy score for clinically tested drug pairs within the cancer cell lines matched to the 591 clinically tested cancer types compared to those drug pairs in non-clinically tested cancer types. 592
KS tests were used to find the d-statistic and p-value. 593 594 595 596 pathway, statistical significance found by the Wilcoxon Test. 624 625 Figure S8 : Model performance. For all models within our suite of drug synergy prediction 626 models the performance was measured when controlled for each "task", or cell line. 627 628 Figure S9 : Correlation of AZ-DREAM score. The Pearson correlation between the provided 629
AstraZeneca-DREAM Challenge score and A) Loewe, B) Bliss, C) ZIP, and D) HSA. 630 631
Supplementary Table  632 Table S1: All features used within our extreme randomized model. Features are listed with their 633 source and the metric used to measure similarity. 634 635 636
